Metabolic Effects of CX3CR1 Deficiency in Diet-Induced Obese Mice

The fractalkine/Cx3CR1 system is implicated in the development of metabolic visceral adipose tissue inflammation in obesity

(2014) Ágnes Polyák et al.   BRAIN BEHAVIOR AND IMMUNITY

Fractalkine (CX3CL1) Is Involved in the Early Activation of Hypothalamic Inflammation in Experimental Obesity

(2014) Joseane Morari et al.   DIABETES

Serum levels of fractalkine are associated with markers of insulin resistance in gestational diabetes

(2014) T. Ebert et al.   DIABETIC MEDICINE

Circulating Fractalkine Levels Predict the Development of the Metabolic Syndrome

(2014) Yin Xueyao et al.   International Journal of Endocrinology

Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway

(2013) Stavros Apostolakis et al.   ACTA PHARMACOLOGICA SINICA

The Fractalkine/CX3CR1 System Regulates β Cell Function and Insulin Secretion

(2013) Yun Sok Lee et al.   CELL

Fractalkine: A Survivor's Guide

(2012) Gemma E. White et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

CX3CR1 Deficiency Does Not Influence Trafficking of Adipose Tissue Macrophages in Mice With Diet-Induced Obesity

(2012) David L. Morris et al.   Obesity

Fractalkine Is a Novel Human Adipochemokine Associated With Type 2 Diabetes

(2011) R. Shah et al.   DIABETES

Association of Common Polymorphisms in the Fractalkine Receptor (CX3CR1) With Obesity

(2010) Dave Sirois-Gagnon et al.   Obesity

Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research

(2010) Carol Kilkenny et al.   PLOS BIOLOGY

Chemokines as Novel Therapeutic Targets for Inflammatory Bowel Disease

(2009) Miyuki Nishimura et al.   Annals of the New York Academy of Sciences

Fractalkine: one chemokine, many functions

(2009) G. E. White et al.   BLOOD

Inflammation Impairs Reverse Cholesterol Transport In Vivo

(2009) Fiona C. McGillicuddy et al.   CIRCULATION